Reduced N-Type Ca\textsuperscript{2+} Channels in Atrioventricular Ganglion Neurons Are Involved in Ventricular Arrhythmogenesis

Dongze Zhang, MD; Huiyin Tu, PhD; Liang Cao, MD; Hong Zheng, MD; Robert L. Muelleman, MD; Michael C. Wadman, MD; Yu-Long Li, MD, PhD

Background—Attenuated cardiac vagal activity is associated with ventricular arrhythmogenesis and related mortality in patients with chronic heart failure. Our recent study has shown that expression of N-type Ca\textsuperscript{2+} channel \(\alpha\)-subunits (Cav2.2-\(\alpha\)) and N-type Ca\textsuperscript{2+} currents are reduced in intracardiac ganglion neurons from rats with chronic heart failure. Rat intracardiac ganglia are divided into the atrioventricular ganglion (AVG) and sinoatrial ganglion. Ventricular myocardium receives projection of neuronal terminals only from the AVG. In this study we tested whether a decrease in N-type Ca\textsuperscript{2+} channels in AVG neurons contributes to ventricular arrhythmogenesis.

Methods and Results—Lentiviral Cav2.2-\(\alpha\) shRNA (2 \(\mu\)L, 2 \(\times\) 10\textsuperscript{7} pfu/mL) or scrambled shRNA was in vivo transfected into rat AVG neurons. Nontransfected sham rats served as controls. Using real-time single-cell polymerase chain reaction and reverse-phase protein array, we found that in vivo transfection of Cav2.2-\(\alpha\) shRNA decreased expression of Cav2.2-\(\alpha\) mRNA and protein in rat AVG neurons. Whole-cell patch-clamp data showed that Cav2.2-\(\alpha\) shRNA reduced N-type Ca\textsuperscript{2+} currents and cell excitability in AVG neurons. The data from telemetry electrocardiographic recording demonstrated that 83% (5 out of 6) of conscious rats with Cav2.2-\(\alpha\) shRNA transfection had premature ventricular contractions (\(P<0.05\) versus 0% of nontransfected sham rats or scrambled shRNA-transfected rats). Additionally, an index of susceptibility to ventricular arrhythmias, inducibility of ventricular arrhythmias evoked by programmed electrical stimulation, was higher in rats with Cav2.2-\(\alpha\) shRNA transfection compared with nontransfected sham rats and scrambled shRNA-transfected rats.

Conclusions—A decrease in N-type Ca\textsuperscript{2+} channels in AVG neurons attenuates vagal control of ventricular myocardium, thereby initiating ventricular arrhythmias. (J Am Heart Assoc. 2018;7:e007457. DOI: 10.1161/JAHA.117.007457.)

Key Words: autonomic nervous system • calcium channel • ECG • ganglia • parasympathetic • vagus nerve • ventricular arrhythmia

Malignant ventricular arrhythmia including ventricular tachycardia (VT) and ventricular fibrillation (VF) is a common complication in chronic heart failure (CHF) and accounts for nearly 50% to 60% of mortality in patients with CHF.\textsuperscript{1-6} Cardiac autonomic dysfunction is a major feature of CHF, characterized by a sustained increase of sympathetic tone and withdrawal of cardiac vagal activity.\textsuperscript{7-9} Much evidence has shown that this autonomic imbalance leads to arrhythmogenesis and is associated with the high mortality of CHF.\textsuperscript{2,10,11} The role of sympathetic hyperactivation in CHF is highlighted by a blockade of the sympathetic nervous system (\(\beta\)-adrenergic receptor blockers) as the key approach to the current therapy of CHF.\textsuperscript{12-14} However, such pharmacological treatment is not ideal because the ability of \(\beta\)-adrenergic receptor blockers to affect cardiac vagal activity is limited,\textsuperscript{15} and survival rates even when \(\beta\)-blockers are used are lower in CHF patients with depressed cardiac vagal activity than in CHF patients with normal cardiac vagal activity.\textsuperscript{16} Although modulation of cardiac vagal activation as a potential therapy has received only limited attention, direct cardiac vagal nerve stimulation has been found to suppress ventricular tachyarrhythmia and to improve survival rates in CHF.\textsuperscript{17-19} Therefore, exploring the mechanism(s) responsible for the impairment of cardiac vagal function can provide a new therapeutic strategy for eliminating ventricular tachyarrhythmia and reducing related mortality.

Cardiac vagal preganglionic fibers originate within the central nervous system at the brainstem (nucleus ambiguus,
Clinical Perspective

What Is New?

- In vivo lentiviral transfection of Cav2.2-α shRNA into the rat atrioventricular ganglion decreases expression of Cav2.2-α mRNA and protein and N-type Ca²⁺ currents in atrioventricular ganglion neurons.
- A decrease in N-type Ca²⁺ channels in atrioventricular ganglion neurons blunts vagal control of the ventricle and initiates ventricular arrhythmogenesis.
- We provide direct evidence that blunted ventricular vagal activity triggers ventricular arrhythmogenesis.

What Are the Clinical Implications?

- Withdrawal of cardiac vagal activity might be involved in occurrence of fatal ventricular arrhythmias in the chronic heart failure state.
- Improvement of the ventricular vagal activity might be an effective therapeutic strategy to limit malignant ventricular arrhythmias and cardiac sudden death in chronic heart failure.

Microinjection of Lentiviral Ca₂⁺,2-α shRNA into the AVG

Under surgical anesthesia (2% isoflurane) and mechanical ventilation, rats were kept in right lateral recumbent position. A left posterolateral thoracotomy was done through the third left intercostal space on the back, and the left lung was moved aside to expose the AVG. There was a white color epicardial adipose pad at the junction of the inferior pulmonary veins and left atrium, which served as a marker for the virus microinjection because the AVG is located in this pad (Figure 1A). The heart beating was very weak at the junction of the inferior pulmonary veins and left atrium when the AVG was exposed under the left posterolateral thoracotomy, which ensured the success of the virus microinjection into the AVG. Under the microscope, lentiviral rat Cav2.2-α shRNA with phosphorylated green fluorescent protein (pGFP) or shRNA scramble control (2×10⁷ pfu/mL, TL713159V and TR30021V, OriGene Technologies, Rockville, MD) was microinjected into the epicardial adipose pad by a glass micropipette connected to a WPI Nanoliter 2000 microinjector (Figure 1A). Scrambled shRNA was used to assess possible toxicity of lentivirus. After transfection, the chest was closed, and experiments were performed 1 week later to guarantee degradation of existing Ca₂⁺,2-α protein.

Efficacy of Lentivirus Infection

Efficacy of the lentivirus infection was assessed by immunofluorescence staining. Briefly, isolated AVGs from 3 rats with transfection of lentiviral rat Ca₂⁺,2-α shRNA with pGFP were postfixed in 4% paraformaldehyde, followed by soaking of AVGs in 30% sucrose for 12 hours at 4°C for cryostat protection. AVGs were cut into 10-μm-thick sections at −20°C and then mounted on precoated glass slides. AVG sections were incubated with 10% donkey serum for 1 hour, followed by incubation with goat anti-choline acetyltransferase antibody (a cholinergic neuronal marker; EMD Millipore, Billerica, MA) overnight at 4°C. Then AVG sections were incubated with fluorescence-conjugated secondary antibody (Invitrogen, Carlsbad, CA) for 1 hour at room temperature. AVG sections were examined under a Leica (Wetzlar, Germany) fluorescent microscope with corresponding filters for choline acetyltransferase (red color) and pGFP (green
color). The imaging was captured by a digital camera system. Figure 1B shows that microinjection of lentiviral rat Cav2.2-α shRNA with pGFP into the AVG induced pGFP expression in almost all choline acetyltransferase–positive AVG neurons (n=3 rats), confirming the efficacy of virus infection and proper microinjection into the AVG.

### Labeling and Isolation of AVG Neurons

Although ventricular myocardium receives projection of nerve terminals only from the AVG,\(^2\),\(^3\) it is possible that the AVG also innervates other parts of the heart. Therefore, we used a transported fluorescent dye (red color DiI) to retrograde-label

---

**Figure 1.** A, AVG microinjection under a rat left posterolateral thoracotomy. LCV indicates left cranial vein; LPV, left pulmonary vein; MPV, middle pulmonary vein. B, Expression of pGFP protein in rat cholinergic AVG neurons after in vivo lentiviral transfection of Cav2.2-α shRNA with pGFP cDNA. C, Expression of Cav2.2-α mRNA in Dil-labeled AVG neurons from all groups of rats, measured by single-cell real-time RT-PCR. N=20 neurons from 6 rats in each group. D, Expression of Cav2.2-α protein in the AVG from all groups of rats, measured by reverse-phase protein microarray. N=3 rats in each group. Data are means±SEM. Statistical significance in Figure 1C-D was determined by 1-way ANOVA with post hoc Dunnett test against the sham group. *P<0.05 vs sham. AVG indicates atrioventricular ganglion; ChAT, choline acetyltransferase; pGFP, phosphorylated green fluorescent protein; RT-PCR, reverse-transcription polymerase chain reaction.
Cardiac Vagal Dysfunction and Arrhythmia

Zhang et al

DOI: 10.1161/JAHA.117.007457

Journal of the American Heart Association

Each rat was anesthetized with 2% isoflurane and artificially ventilated. After a left thoracotomy was performed to expose the heart, 8 injections (2 μL Dil for each injection) were made subepicardially into the left ventricular myocardium using a glass micropipette connected to a WPI (Sarasota, FL) Nanoliter 2000 microinjector.23 The surgical incision was closed, and terminal experiments were performed at least 3 days after labeling surgery because we found that 3 days are needed for dye diffusion to the neurons.23 Dil-labeled AVG neurons (ventricular vagal neurons) were used to perform single-cell real-time reverse-transcription (RT) polymerase chain reaction (PCR) and whole-cell patch-clamp recording.

ECG Transmitter Implantation and Electrocardiographic Recording

Each rat was anesthetized with 2% isoflurane (Butler Schein Animal Health, Dublin, OH). The skin was first shaved and sterilized. After laparotomy was performed at the linea alba (abdomen), the radiotelemetry ECG transmitter26 (TRM54PB, Millar Instruments, Houston, TX) was placed into the abdominal cavity and secured to the abdominal wall at the best position for battery recharging and signal communication. In accordance with the Millar User Manual for ECG recording, bipolar electrodes were tunneled subcutaneously. The negative lead was secured in the upper sternal midline, and the positive lead was attached to the underlying tissue near the left side of the xiphoid process. In order to reduce the electrical noise during ECG recording, electrical leads were kept together and run alongside each other as far as practical. All incisions were sutured in 2 layers. ECG recording was performed after 1 week of recovery.

For ECG recording, rats were placed on a SmartPad receiver (Millar Instruments, Houston, TX). For quantification of ventricular arrhythmic events, 24-hour continuous ECG signals were acquired at room temperature from unrestrained, conscious rats. Real-time ECG signals were digitalized and analyzed by PowerLab 8/30 Data Acquisition System with LabChart 7 software and ECG analysis module (AD Instruments, Colorado Springs, CO). The number of premature ventricular contractions (PVCs) and cumulative duration of VT/VFs were acquired at room temperature from unrestrained, conscious rats. Real-time ECG signals were digitalized and analyzed by PowerLab 8/30 Data Acquisition System with LabChart 7 software and ECG analysis module (AD Instruments, Colorado Springs, CO). The number of premature ventricular contractions (PVCs) and cumulative duration of VT/VFs were counted manually during 24-hour continuous ECG recording. VT was defined as PVCs lasting ≥4 beats. VF was defined as rapid, irregular QRS complexes. QT and QTc intervals as well as dispersions (QTd and QTcd) were calculated from ECG recordings using LabChart 7 software.27 A QTc interval was calculated by the Bazett formula (QT/√RR, where RR is the RR interval). As an index of the spatial dispersion of the ventricular repolarization, QTd and QTcd were calculated by equations: QTd=QTmax−QTmin and QTcd=QTcmax−QTcmin, where QTmax and QTcmax are the maximum QT interval and the maximum QTc interval; QTmin and QTcmin are the minimum QT interval and the minimum QTc interval.27 The T-peak to T-end interval (Tpe), another marker of transmural dispersion of the ventricular repolarization, was calculated from ECG recordings to serve as an ECG marker of ventricular arrhythmia.28

Measurement of Susceptibility to Ventricular Arrhythmias

Susceptibility to ventricular arrhythmias was measured as described previously.26 On the day of the terminal experiment (1 day after radiotelemetry ECG recording), each rat was anesthetized (800 mg/kg urethane combined with 40 mg/kg α-chloralose, intraperitoneally). The animal’s trachea was cannulated to facilitate mechanical respiration. The animal’s body temperature was maintained at 37°C with an Animal Temperature Controller (ATC 1000; World Precision Instruments, Sarasota, FL). Surface lead-II ECG was recorded using subcutaneous electrodes connected to a biological amplifier (AD Instruments, Colorado Springs, CO). A left thoracotomy was then performed in the fourth intercostal space. After the heart was visualized, the pericardium was carefully removed. A bipolar platinum stimulating electrode was placed on the right ventricle outflow tract for programmed electrical stimulation (PES). The PES was performed by a programmed electrical stimulation stimulator (Digital Pulse Generator 1831, WPI) and an isolator (A320R Isostim Stimulator, WPI). The pulse current output was set to a twice capture threshold and a 2-millisecond pulse width. To determine the ventricular effective refractory period, a train of 8 stimuli (8×S1) at a 120-millisecond cycle length was applied, followed by an extra stimulus (S2). Starting at 90 milliseconds, the S1 to S2 interval was reduced in steps of 2 milliseconds until the ventricular effective refractory period was identified. Based on the ventricular effective refractory period, a programmed stimulation protocol combined by single (S2), double (S3), or triple extra stimulus (S4) after a train of 8 stimuli (8×S1) was designed to induce ventricular tachyarrhythmias. The end point of ventricular pacing was induction of ventricular tachyarrhythmia. Ventricular tachyarrhythmia was considered noninducible when the PES induced either no ventricular premature beats or self-terminated ventricular premature beats <6. Ventricular tachyarrhythmia was considered as nonsustained when it lasted ≤15 beats and sustained when it lasted >15 beats before spontaneously terminating.

Inducibility of ventricular tachyarrhythmia was quantified by a quotient of ventricular arrhythmic scores: 0, noninducible preparations; 1, nonsustained tachyarrhythmias induced with 3 extra stimuli; 2, sustained tachyarrhythmias induced with 3 extra stimuli; 3, nonsustained tachyarrhythmias induced with 2 extra stimuli; 4, sustained tachyarrhythmias induced with 2

DOI: 10.1161/JAHA.117.007457

Journal of the American Heart Association

4
extra stimuli; 5, nonsustained tachyarrhythmias induced with 1 extra stimulus; 6, sustained tachyarrhythmias induced with 1 extra stimulus; 7, tachyarrhythmias induced during a train of 8 stimuli (8 × S1) at a basic cycle length of 120 milliseconds; 8, the heart stopped before the PES.

Measurement of Hemodynamics and Vagal Control of Ventricular Function

After the susceptibility to ventricular arrhythmias had been detected, the left femoral artery was cannulated with a polyethylene-50 catheter for measurement of blood pressure and heart rate.26 A Millar pressure transducer (SPR 524; Millar Instruments, Houston, TX) was slowly inserted into the right carotid artery and carefully advanced to the left ventricle for measurement of left ventricular pressure and the maximum rate of left ventricular pressure rise. Hemodynamic data were recorded by powerLab 8/30 Data Acquisition System with LabChart 7 software (AD Instruments, Colorado Springs, CO). Then, bilateral cervical vagal nerves, cervical sympathetic nerves, and aortic depressor nerves were isolated and transected to avoid influence of the arterial baroreflex. Because we found that the response of left ventricular systolic pressure (LVSP) to left vagal efferent nerve stimulation was markedly stronger than that to right vagal efferent nerve stimulation, the peripheral end of the left vagal nerve was placed on a bipolar stimulating electrode for vagal efferent nerve stimulation. Left vagal efferent nerve stimulation was applied by a Grass S9 stimulator (Grass Instruments, Quincy, MA) with 10 seconds of constant-frequency stimulation (0.1 milliseconds pulse duration and intensity of 7.5 V, 1-100 Hz). As the index of vagal control of ventricular function, changes of LVSP and maximum rate of left ventricular pressure rise in response to different frequencies of left efferent vagal stimulation were recorded by a PowerLab 8/30 data acquisition system with LabChart 7 software (AD Instruments, Colorado Sprinings, CO).

Isolation of AVG Neurons and Single-Cell Real-Time RT-PCR

After in-vivo experiments were performed, the AVG, located in a white epicardial adipose pad at the junction of inferior pulmonary veins and left atrium, was exposed. AVG neurons were isolated by a 2-step enzymatic digestion protocol, as described previously.23,29 Isolated AVG was placed in ice-cold modified Tyrode solution (mmol/L): 140 NaCl, 5 KCl, 10 HEPES, and 5 glucose. The AVG was minced with microscissors and incubated with a modified Tyrode solution containing 0.1% collagenase and 0.1% trypsin for 30 minutes at 37°C. The tissue was then transferred to a modified Tyrode solution containing 0.2% collagenase and 0.5% bovine serum albumin for 30 minutes of incubation at 37°C. The isolated neurons were cultured at 37°C in a humidified atmosphere of 95% air-5% CO2 for single-cell real-time RT-PCR and patch-clamp experiments.

Single-cell real-time RT-PCR was performed as described previously.23 Briefly, isolated AVG neurons were loaded in a chamber with regular extracellular solution (in mmol/L): 137 NaCl, 5.4 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 10 glucose with pH 7.4. Dil-labeled AVG neurons (ventricular vagal neurons) were used for single-cell real-time RT-PCR. A patch-clamp pipette (1-3 MΩ resistance) was used to break the membrane of single neuronal cell. Under the suction condition, cell and pipette content were expelled into a 0.2-mL PCR tube containing mRNA preserving reagents and then mixed with RT reaction buffer. RT was performed at 42°C for 30 minutes, and the cDNA was then stored at −80°C. The primers (Table 1) were based on the cDNA sequences of RPL19 (housekeeping gene) and Ca,2.2-α. PCR reaction was performed in a 25-μL volume containing 12.5 μL iQ Syber Green Supermix (Bio-Rad, Hercules, CA), 200 nmol/L (in the first round) or 300 nmol/L (in the second round) of each primer. The cDNA was amplified by real-time quantitative PCR with an ABI StepOnePlus Real-Time PCR System. For quantification, Ca,2.2-α gene was normalized to housekeeping gene RPL19. The data were analyzed by the 2−ΔΔCt method.30

Reverse-Phase Protein Microarray for Protein Expression

Due to the limitation of small AVG samples (1-2 mg wet weight), we could not detect the expression of Ca,2.2-α protein using regular Western blot analyses and instead employed a modified reverse-phase protein microarray, which is highly sensitive and needs about 1 μg protein.31 Briefly, total protein concentration of AVG samples was determined using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Fifty nanoliters of each protein sample was loaded onto nitrocellulose-coated glass slides by an 8-pin arrayer. After protein samples were sequentially incubated with primary antibodies (rabbit anti-Ca,2.2-α antibody and mouse anti-β-

Table 1. Primer Sequences

| Gene Accession | Primer Name | Primer Sequence (5’-3’) |
|----------------|-------------|------------------------|
| NM0147141      | Ca,2.2-forward | TTCTTAGCCAGGTTCCCATC |
|                | Ca,2.2-reverse   | CTTTCCAGGCGCTTCTGCTTC |
|                | Ca,2.2-internal  | CCACCACCGCCTGCGCCTGCGC |
| NM031103       | RPL19-forward   | TGAAAGTCAAGGAAATGTTTC |
|                | RPL19-reverse   | TTGGTGGTCTCTTGCTTAGAC |
|                | RPL19-internal  | TGGAGGCGCTAGACTGGTACCG |
actin antibody) and LI-COR fluorescence-conjugated secondary antibodies (IRDye 800CW goat anti-rabbit IgG and IRDye 680LT goat anti-mouse IgG), the protein signals were scanned with a LI-COR Odyssey IR imaging system (LI-COR, Lincoln, NE). Before reverse-phase protein microarray was performed, Western blot analysis was used to validate target specificity in the supernatant was determined using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL). The protein concentration in the supernatant was determined using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL). The signal was detected using enhanced chemiluminescence substrate (Pierce Chemical), and all bands were analyzed using a UVP bioimaging system (UVP, Upland, CA). Anti-Ca$_{v2.2}$-α antibody recognized proteins of 250 and 220 kDa, 2 size forms of Ca$_{v2.2}$-α subunit in the rat brain$^{34,35}$ but not in the rat skeletal muscle. All bands disappeared when antigenic peptide was preincubated (Figure 2).

**Whole-Cell Patch-Clamp Recording for Ca$^{2+}$ Currents and Action Potentials**

After isolation of AVG neurons (see above), voltage-gated Ca$^{2+}$ currents and action potentials were recorded only in Dil-labeled AVG neurons (ventricular vagal neurons) by the whole-cell patch-clamp technique using an Axopatch 200B patch-clamp amplifier (Molecular Devices, Sunnyvale, CA)$^{23}$.

In voltage-clamp experiments, resistance of the patch pipette was 4 to 6 MΩ when the pipette was filled with the following solution (in mmol/L): 120 CsCl, 1 CaCl$_2$, 40 HEPES, 11 EGTA, 4 MgATP, 0.3 Tris-GTP, 14 creatine phosphate, and 0.1 leupeptin (pH 7.3; 305 mosmol/kg). The extracellular solution consisted of (in mmol/L): 140 TEA-Cl, 5 BaCl$_2$, 1 MgCl$_2$, 10 HEPES, 0.001 TTX, 2 4-AP, and 10 glucose (pH 7.4; 310 mosmol/kg). Series resistance of 5 to 13 MΩ was electronically compensated at 30% to 80%. The junction potential was calculated to be +7.9 mV using the P-clamp 10.2 program (Molecular Devices, Sunnyvale, CA), and all values of membrane potential given throughout were corrected using this value. Current traces were sampled at 10 kHz and filtered at 5 kHz. The holding potential was −80 mV, and current-voltage relationships were elicited by 5-mV step increments to potentials between −60 and 60 mV for 500 milliseconds. N-type Ca$^{2+}$ currents were obtained by subtracting the Ca$^{2+}$ currents under treatment with ω-conotoxin GVI A from total Ca$^{2+}$ currents. Based on the previous study, the concentration of ω-conotoxin GVIA (1 μmol/L, a specific N-type Ca$^{2+}$ channel blocker) used in the present study is a saturating concentration for inhibiting N-type Ca$^{2+}$ channels$^{23,36}$.

Peak currents were measured for each test potential, and current density was calculated by dividing peak current by cell membrane capacitance.

---

DOI: 10.1161/JAHA.117.007457

Journal of the American Heart Association
In current-clamp experiments action potentials were elicited by a ramp current injection of 0 to 100 pA, and frequency of action potentials was measured in a 1-second current clamp. The patch-pipette solution was composed of (in mmol/L): 105 K-aspartate, 20 KCl, 1 CaCl₂, 5 MgATP, 10 HEPES, 10 EGTA, and 25 glucose (pH 7.2; 320 mosmol/kg). The bath solution was composed of (in mmol/L): 140 NaCl, 5.4 KCl, 0.5 MgCl₂, 2.5 CaCl₂, 5.5 HEPES, 11 glucose, and 10 sucrose (pH 7.4; 330 mosmol/kg). Junction potential was calculated to be +12.3 mV, and membrane potential was corrected using this value. The P-clamp 10.2 program (Molecular Devices, Sunnyvale, CA) was used for data acquisition and analysis. All experiments were done at room temperature (22-24°C).

**Statistical Analysis**

All data are presented as means±SEM. SigmaPlot 12 (Systat Software, Chicago, IL) was used for data analysis. We analyzed the normal distribution of the data using the Kolmogorov-Smirnov test and found that statistical analyses for the normal distribution of the data are passed in all parameters. Statistical significance was determined by a Fisher exact test for incidence of ventricular arrhythmias because some cells have fewer than 5 expected observations. Statistical significance was determined by 1-way ANOVA with post hoc Dunnett test against the sham group for most of the parameters. Statistical significance in some experiments was determined by 1-way repeated-measures ANOVA with post hoc Dunnett test against the sham group. Statistical significance was determined by paired t-test for comparison between before and after treatments. Because of the heterogeneity among the dissociated neurons from 1 animal, we used neuron numbers to do statistical analyses for Cav2.2-α mRNA, N-type Ca²⁺ currents, and action potentials. Statistical significance was accepted when P<0.05.

**Results**

**Efficacy of Lentiviral Cav2.2-α shRNA**

To verify efficacy of lentiviral Cav2.2-α shRNA transfected into the AVG, expression of Cav2.2-α mRNA and protein in AVG neurons was measured in all groups of rats. We initially confirmed that there was expression of Cav2.2-α mRNA and protein in AVG neurons from sham rats. In vivo lentiviral transfection of Cav2.2-α shRNA into the AVG reduced expression of Cav2.2-α mRNA and protein in AVG neurons, which were about 43% and 52% of Cav2.2-α mRNA and protein levels seen in sham AVG neurons, respectively (Figure 1C and 1D). However, shRNA scramble control had no effect on expression of Cav2.2-α mRNA and protein in AVG neurons (Figure 1C and 1D).

**Influence of Ca₂⁺.2-α shRNA on N-Type Ca²⁺ Currents and Cell Excitability in AVG Neurons**

Voltage-gated Ca²⁺ currents and action potentials in DiI-labeled AVG neurons (ventricular vagal neurons) were recorded by whole-cell patch-clamp technique. A specific N-type Ca²⁺ channel blocker (1 μmol/L ω-conotoxin GVIA) was used to separate N-type Ca²⁺ currents from total Ca²⁺ currents. N-type Ca²⁺ currents were obtained by subtracting Ca²⁺ currents under treatment with ω-conotoxin GVIA from total Ca²⁺ currents (Figure 3Aa). Cav2.2-α shRNA but not shRNA scramble control decreased N-type Ca²⁺ currents in ventricular vagal neurons (Figure 3Aa through Ac). Cav2.2-α shRNA also reduced frequency of action potentials (a parameter of the cell excitability) in ventricular vagal neurons (Figure 3Ba and Bb). However, there were no significant differences in resting membrane potential, input resistance, and cell membrane capacitance in ventricular vagal neurons from all groups of rats (Table 2).

**Ca₂⁺.2-α shRNA Attenuated Vagal Control of the Ventricle**

We hypothesized that attenuated ventricular vagal activity through in vivo transfection of Cav2.2-α shRNA into AVG neurons could be linked to ventricular arrhythmogenesis. Activation of the vagal efferent nerve results in a negative inotropic effect in the ventricle, which serves as an index of ventricular vagal function. Cav2.2-α shRNA transfection into AVG neurons significantly blunted changes of the LVSP and maximum rate of left ventricular pressure rise in response to vagal efferent nerve stimulation, compared with sham rats (Figure 4). However, shRNA scramble control did not show any effect on vagal control of the ventricle. Additionally, transfection of Cav2.2-α shRNA into AVG neurons increased basal LVSP with the absence of heart-rate changes (Table 3), which further confirmed that transfection of Cav2.2-α shRNA into AVG neurons only blunted ventricular vagal activity and did not affect sinoatrial vagal activity.

**Effect of Ca₂⁺.2-α shRNA on Susceptibility to Ventricular Arrhythmias in Anesthetized Rats**

Figure 5 shows the effect of Cav2.2-α shRNA on the susceptibility to ventricular arrhythmias in anesthetized rats (Figure 5). A PES protocol was performed to induce ventricular arrhythmias in anesthetized rats, and an inducibility quotient was used to evaluate the susceptibility to ventricular arrhythmias. Ventricular arrhythmias were not induced by S₁S₂S₃S₄ programmed stimulation, and the inducibility quotient of ventricular arrhythmias was 0 in sham rats (Figure 5). After in vivo transfection of Cav2.2-α shRNA into AVG neurons, 83.3% (5/6) of the rats had PES-induced ventricular arrhythmias, and the inducibility quotient of ventricular arrhythmias was 1.97±0.49 (Figure 5; P<0.05 versus

DOI: 10.1161/JAHA.117.007457
sham rats). However, there was nonoccurrence of PES-induced ventricular arrhythmias in rats with transfection of shRNA scramble control (Figure 5).

Effect of Cav2.2-α shRNA on Spontaneous Ventricular Arrhythmias and ECG Parameters in Conscious Rats

Spontaneous ventricular arrhythmias and ECG parameters in conscious rats were monitored by radiotelemetry ECG recording (Figures 6 and 7). There was nonoccurrence of spontaneous ventricular arrhythmias in sham rats (0/6 of the rats, Figure 6). After in vivo transfection of Cav2.2-α shRNA into AVG neurons, 83.3% (5/6) of the rats had PVCs, and the number of spontaneous PVCs was 10±4 beats/h (Figure 6; P<0.05 versus sham rats). In vivo transfection of shRNA scramble control into AVG neurons did not induce spontaneous ventricular arrhythmias (Figure 6).

Simultaneously, in vivo transfection of Cav2.2-α shRNA into AVG neurons increased the QT interval, QTc interval, QTd, QTcd, and Tpe, compared with sham rats or before treatment with Cav2.2-α shRNA (Figure 7; P<0.05). However, scrambled shRNA did not affect these arrhythmia-related ECG parameters (Figure 7).
In the present study we tested the influence of reduced N-type Ca\textsuperscript{2+} channels in ventricular vagal neurons located in the AVG on ventricular arrhythmogenesis and documented the following findings. First, in vivo transfection of Ca\textsubscript{v}2.2-a shRNA into AVG neurons decreased expression and ion currents of N-type Ca\textsuperscript{2+} channels and cell excitability in ventricular vagal neurons. Second, in vivo transfection of Ca\textsubscript{v}2.2-a shRNA into AVG neurons attenuated vagal control of the ventricle. Third, in vivo transfection of Ca\textsubscript{v}2.2-a shRNA into AVG neurons increased the susceptibility to ventricular arrhythmias in anesthetized rats. Finally, in vivo transfection of Ca\textsubscript{v}2.2-a shRNA into AVG neurons induced occurrence of PVCs and changes of arrhythmia-related ECG parameters including prolongation of QT, QTc, and Tpe and increase in QTd and QTcd in conscious rats. These findings suggest that a decrease in N-type Ca\textsuperscript{2+} channels in ventricular vagal neurons blunts ventricular vagal activity and triggers ventricular arrhythmogenesis.

Like a natural yin-yang pair, the sympathetic and parasympathetic nervous systems play an important regulatory role in heart functions including cardiac electrophysiology and cardiac muscle contraction. In particular, a sustained increase of sympathetic activity and a marked decrease of parasympathetic tone are used as distinctive hallmarks of CHF.\textsuperscript{7-9} Thus far, most of the studies used the analysis of heart-rate variability and arterial baroreflex sensitivity to evaluate cardiac sympathetic and parasympathetic autonomic activity in physiological and pathophysiological conditions.\textsuperscript{38} Although traditional teaching has stated that cardiac vagal postganglionic nerves regulate the heart through slowing sinus rate and atrioventricular conduction, with little influence on ventricles, and ventricular vagal innervation is considered to be sparse,\textsuperscript{18,39} newer histological techniques have challenged this traditional principle and affirmed dense vagal innervation in the ventricle from all species.\textsuperscript{18,40-43} Recent studies have demonstrated that functionally significant parasympathetic control of ventricular contractile function and excitability exists in rats, and vagal preganglionic neurons of the dorsal motor nucleus contribute to the vagal control of ventricular contractility and excitability.\textsuperscript{44,45} Therefore, directly examining ventricular vagal activity is very useful to assess the vagal modulation of ventricular arrhythmia and contractile dysfunction. Cardiac vagal postganglionic neurons are located in the intracardiac ganglia. Rat intracardiac ganglia are divided into the sinoatrial ganglion and the AVG.\textsuperscript{24} The ventricular myocardium only receives the projection of nerve terminals

**Table 2.** Electrophysiological Changes on Cell Membrane Properties in DiI-Labeled AVG Neurons From All Groups of Rats

|                | Sham          | Scrambled shRNA | Ca\textsubscript{v}2.2-a shRNA |
|----------------|---------------|-----------------|-------------------------------|
| RMP, mV        | 60.1±1.1      | 60.4±1.3        | 59.9±1.2                      |
| R\textsubscript{in}, Q\textsubscript{Ω} | 0.79±0.09     | 0.81±0.08       |                               |
| C\textsubscript{mem}, pF  | 32.4±1.7      | 32.6±1.4        | 32.2±1.4                      |

Data are means±SEM; n=8 neurons from 6 rats in each group. Statistical significance was determined by 1-way ANOVA with post hoc Dunnett test against the sham group. AVG indicates atrioventricular ganglion; C\textsubscript{mem}, cell membrane capacitance; R\textsubscript{in}, input resistance; RMP, resting membrane potential.
from the AVG. In our present study we measured the left ventricular pressure and vagal efferent nerve stimulation-induced negative inotropic response in the left ventricle; the latter serves as an index of ventricular vagal activity. In vivo transfection of Ca_{2.2-α} shRNA into AVG neurons increased basal LVSP with the absence of heart-rate changes in anesthetized rats (Table 3). In vivo transfection of Ca_{2.2-α} shRNA into AVG neurons also attenuated changes of the LVSP and maximum rate of left ventricular pressure rise in response to left vagal efferent nerve stimulation (Figure 4). These results not only confirmed that ventricular contractile function is directly regulated by ventricular vagal postganglionic neurons located in the AVG but also clarified that ventricular vagal activity is attenuated by a decrease in N-type Ca^{2+} channels in ventricular vagal postganglionic neurons.

Fatal ventricular arrhythmias including VT and VF are associated with high mortality in patients with CHF. Based on the fact that the occurrence of fatal ventricular arrhythmias is accompanied by a marked decrease of parasympathetic activity in CHF, some studies demonstrate that decreased parasympathetic activity is correlated with malignant ventricular arrhythmogenesis in the CHF state. Recent studies have also found that the parasympathetic activation induced by vagal nerve stimulation prevents fatal

![Figure 5](link to image)

**Figure 5.** A, Raw data for induction of ventricular arrhythmias evoked by programmed electrical stimulation (S1-4). B and C, Incidence and inducibility quotient of ventricular arrhythmias in all groups of rats. Data are means±SEM; n=6 rats in each group. Statistical significance was determined by Fisher exact test (B) or 1-way ANOVA with post hoc Dunnett test against the sham group (C), respectively. *P<0.05 vs sham.

### Table 3. Basal Hemodynamic Characteristics in All Groups of Anesthetized Rats

|                     | Sham (n=6) | Scrambled shRNA (n=6) | Ca_{2.2-α} shRNA (n=12) |
|---------------------|------------|-----------------------|-------------------------|
| Body weight, g      | 358.4±5.6  | 356.2±7.4             | 359.4±5.3               |
| MBP, mm Hg          | 102.6±3.6  | 103.7±3.5             | 103.5±2.7               |
| HR, bpm             | 349±5      | 351±7                 | 354±5.2                 |
| LVSP, mm Hg         | 120.6±3.1  | 121.5±3.6             | 144.9±3.2               |
| LVEDP, mm Hg        | 1.9±0.3    | 2.0±0.4               | 2.0±0.3                 |
| LV dP/dt_{max}, mm Hg/s | 5918.4±204.4  | 5999.3±225.3         | 6472.7±187.8           |

Mean blood pressure (MBP), heart rate (HR), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), and the maximum rate of left ventricular pressure rise (LV dP/dt_{max}) were measured under anesthetized condition on the day of the terminal experiment. Data are means±SEM. Statistical significance was determined by 1-way ANOVA with post hoc Dunnett test against the sham group. *P<0.05 vs sham.
ventricular arrhythmias and improves survival rates in animal CHF models. However, there is no direct evidence to clarify the role of decreased parasympathetic activity in ventricular arrhythmogenesis and how decreased parasympathetic activity links to ventricular arrhythmogenesis in CHF due to the coexistence of multiple factors in the CHF state (such as sympathetic overactivation, ventricular morphological changes, and others). In the present study in vivo transfection of Cav2.2-α shRNA into AVG neurons decreased expression and ion currents of N-type Ca2+ channels and cell excitability in ventricular vagal neurons (Figures 1 and 3) and blunted the ventricular vagal activity (Figure 4) as well as increased the susceptibility to ventricular arrhythmias of anesthetized rats (Figure 5). More importantly, ECG data obtained from radiotelemetry recording demonstrated that in vivo transfection of Cav2.2-α shRNA into AVG neurons not only increased the QT interval, QTc interval, QTd, QTcd, and Tpe but also induced a spontaneous ventricular tachyarrhythmia in conscious rats (Figures 6 and 7). It has been found that prolongation of the QT and QTc intervals, increase of the QTd and QTcd (a marker of spatial heterogeneity of ventricular repolarization), and prolonged Tpe (a marker of transmural dispersion of ventricular repolarization) are associated with increased risk of malignant ventricular arrhythmias and sudden cardiac death. The results in the present study provide direct evidence that blunted ventricular vagal activity increases the susceptibility to ventricular arrhythmias and induces ventricular arrhythmias.

Our recent study has demonstrated that the occurrence of lethal ventricular arrhythmias is accompanied by reduced N-type Ca2+ currents in AVG neurons and blunted ventricular vagal activity in coronary artery ligation-induced CHF rats. In the present study, although in vivo transfection of Cav2.2-α shRNA into AVG neurons significantly decreased expression and ion currents of N-type Ca2+ channels in ventricular vagal

**Figure 6.** Representative data of ECG recording (A), mean data for incidence of ventricular arrhythmia (B), and the number of premature ventricular contraction (PVC) in all groups of conscious rats. Data are means±SEM; n=6 rats in each group. Statistical significance was determined by Fisher exact test (B) or by 1-way ANOVA with post hoc Dunnett test against the sham group (C). *P<0.05 vs sham.

DOI: 10.1161/JAHA.117.007457
neurons and blunted ventricular vagal activity, it merely induced spontaneous PVCs but not lethal ventricular arrhythmias such as VT/VF in conscious rats. In general, the combination of proarrhythmic substrates and triggers is necessary to initiate lethal ventricular arrhythmias under the CHF state. Besides blunted ventricular vagal activity, therefore, other determinants of ventricular arrhythmias such as myocardial infarction and sympathetic overactivation are the prerequisite factors for fatal ventricular arrhythmogenesis.

Because of the limitation of small AVG samples (1-2 mg wet weight), we could not detect expression of Ca²⁺.2-α mRNA and protein using regular real-time RT-PCR and Western blot analyses and instead employed single-cell real-time RT-PCR and modified reverse-phase protein microarray. Before performing reverse-phase protein microarray, therefore, we used the rat brain as a Ca²⁺.2-α-positive sample and the gastrocnemius muscle as a Ca²⁺.2-α-negative sample to evaluate target specificity of Ca²⁺.2-α antibody (Figure 2). Additionally, we do realize a possible limitation of small animals for extrapolating the findings obtained in this study to humans, although the rat has contributed markedly to assessment of the pathophysiology and treatment of CHF and to the advancement of clinical care. Large animals could be an appropriate alternative for translational experiments. However, the lack of genetic and molecular tools (including a viral vector carrying large-animal genes or shRNAs, and antibodies for large animals) does not allow us to use large animals for these experiments in this study.

A hallmark of CHF, withdrawal of cardiac vagal activity, is associated with ventricular arrhythmogenesis, yet sites and mechanisms involved in abnormal cardiac vagal activity remain unclear. Although our recent study demonstrates that the decrease of N-type Ca²⁺ currents in AVG neurons correlates with occurrence of ventricular arrhythmias in Figure 7. A, Representative signal of electrocardiographic recordings illustrating QT intervals and T-peak to T-end interval (Tpe) in sham and Ca²⁺.2-α shRNA transfected rats. B through F, Mean data for QT intervals, QTc intervals, QT dispersions (QTd), QTc dispersions (QTcd), and Tpe in all groups of conscious rats. Data are means±SEM; n=6 rats in each group. Statistical significance was determined by 1-way ANOVA with post hoc Dunnett test against the sham group for comparison among multiple groups or by paired t test for comparison between before and after treatments, respectively. *P<0.05 vs sham; †P<0.05 vs before treatment. DOI: 10.1161/JAHA.117.007457
CHF rats, we could not clarify whether the occurrence of ventricular arrhythmia in CHF rats is totally or partially due to neuronal remodeling of AVG neurons. This is because these experiments were performed with both coronary artery ligation-induced CHF and other determinants of ventricular arrhythmias, such as CHF-induced changes of ventricular myocytes themselves. Our current study decreases N-type Ca2+ channels in AVG neurons and ventricular vagal activity in sham rats without changing the above factors. Therefore, this current study provides direct evidence that blunted ventricular vagal activity is a determinant of ventricular arrhythmogenesis to increase the susceptibility to ventricular arrhythmias and initiate ventricular arrhythmias as a trigger. Improvement of the ventricular vagal activity might be an effective therapeutic strategy to limit malignant ventricular arrhythmias and cardiac sudden death in patients with CHF.

Sources of Funding
This study was supported by the American Heart Association (Grant-in-Aid 15GRANT24970002 to Li), and National Heart, Lung, and Blood Institute (grant R01HL-137832A to Li).

Disclosures
None.

References
1. Carson P, Anand I, O’Connor C, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, Barnett JH, Feldman AM, Bristow MR. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2329–2334.
2. Cygankiewicz I, Zareba W, Vazquez R, Valverdu M, Gonzalez-Juanatey JR, Valdes M, Almendral J, Cinca J, Caminal P, de Luna AB. Heart rate turbulence predicts all-cause mortality and sudden death in congestive heart failure patients. Heart Rhythm. 2008;5:1095–1102.
3. Huiak HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–1482.
4. Podrid PJ, Fogel RL, Fuchs TT. Ventricular arrhythmia in congestive heart failure. Am J Cardiol. 1992;69:82G–95G.
5. Singh BN. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Heart Fail Rev. 2002;7:285–300.
6. Thompson BS. Sudden cardiac death and heart failure. AACV Adv Crit Care. 2009;20:356–365.
7. Porter TR, Eckberg DL, Fritsch JM, Rea RF, Beightol LA, Schmedtje JF Jr, Valdes M, Almendral J, Cinca J, Caminal P, de Luna AB. Heart rate turbulence predicts all-cause mortality and sudden death in congestive heart failure patients. Heart Rhythm. 2008;5:1095–1102.
8. Saud JP, Ayai Y, Berger RD, Lilly LS, Colucci WS, Cohen RJ. Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. Am J Cardiol. 1986;5:1292–1299.
9. Schwartz PJ, De Ferrari GM. Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations. J Clin Invest. 1990;85:1362–1371.
10. Paul H, Jellfelt C, Sylvestre A, et al. Ventricular arrhythmia in heart failure: imaging technique and clinical implications. Curr Cardiol Rev. 2011;7:35–42.
11. Hauptman PJ, Schwartz PJ, Gold MR, Borggreve M, Van Veldhuisen DJ, Starling RC, Mann DL. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J. 2012;163:954–962.
12. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation. 2003;107:1570–1575.
13. Akiyama T, Yamazaki T. Adrenergic inhibition of endogenous acetylcholine release on postganglionic cardiac vagal nerve terminals. Cardiovasc Res. 2000;46:531–536.
14. Tu H, Li J, Zhang D, Zheng H, Patel KP, Cornish KG, Wang WZ, Muelemann RL, Li YL. Heart failure-induced changes of voltage-gated Ca2+ channels and cell excitability in rat postganglionic neurons. Am J Physiol Cell Physiol. 2014;306:C132–C142.
15. Sampaio KN, Mauad H, Muelemann RL, Ford TW. Differential chronotropic and dromotropic responses to focal stimulation of cardiac vagal ganglia in the rat. Exp Physiol. 2003;88:315–327.
16. Pardini BJ, Patel KP, Schmid PG, Lund DD. Location, distribution and projections of intracardiac ganglion cells in the rat. J Auton Nerv Syst. 1987;20:91–101.
17. Zhang D, Tu H, Wang C, Cao L, Muelemann RL, Wadman MC, Li YL. Correlation of ventricular arrhythmogenesis with neuronal remodeling of cardiac postganglionic parasympathetic neurons in the late stage of heart failure after myocardial infarction. Front Neurosci. 2017;11:252.
18. Costa EC, Goncalves AA, Areas MA, Morgabiel RG. Effects of metformin on QT and QTC interval dispersion of diabetic rats. Arq Bras Cardiol. 2008;90:232–238.
19. Yagishita D, Chui RW, Yamakawa K, Rajendran PS, Ajijola OA, Nakamura K, So EL, Mahajian A, Shikumura K, Vaseghi M. Sympathetic nerve stimulation, not circulating norepinephrine, modulates T-peak to T-end interval by increasing global dispersion of repolarization. Circ Arrhythm Electrophysiol. 2015;8:174–185.
20. Liu J, Tu H, Zheng H, Zhang L, Tran TP, Muelemann RL, Li YL. Alterations of calcium channels and cell excitability in intracardiac ganglion neurons from type 2 diabetic rats. Am J Physiol Cell Physiol. 2012;302:C1119–C1127.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
22. Gallagher RI, Silvestri A, Petricoin EF III, Liotta LA, Espina V. Reverse phase protein microarrays: fluorometric and colorimetric detection. Methods Mol Biol. 2011;722:275–301.
23. Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, Schwartz A, Snutch TP, Tanabe T, Birnbaumer L, Tissen JW, Catterall WA. Nomenclature of voltage-gated calcium channels. Neuroen. 2000;25:533–535.
24. Trimmer JS, Rhodes KJ. Localization of voltage-gated ion channels in mammalian brain. Annu Rev Physiol. 2004;66:477–519.
25. Westenbroek RE, Hell JW, Warner C,Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron. 1992;9:1099–1115.
Cardiac Vagal Dysfunction and Arrhythmia

35. Hell JW, Appleyard SM, Yokoyama CT, Warner C, Catterall WA. Differential phosphorylation of two size forms of the N-type calcium channel alpha 1 subunit which have different COOH termini. J Biol Chem. 1994;269:7390–7396.

36. Jeong SW, Wurster RD. Calcium channel currents in acutely dissociated intracardiac neurons from adult rats. J Neurophysiol. 1997;77:1769–1778.

37. Lewis ME, Al-Khalidi AH, Bonser RS, Clutton-Brock T, Morton D, Paterson D, Townend JN, Coote JH. Vagus nerve stimulation decreases left ventricular contractility in vivo in the human and pig heart. J Physiol. 2001;534:547–552.

38. Machhada A, Ang R, Ackland GL, Ninkina N, Buchman VL, Gourine AV. Origins of the dorsal drive controlling left ventricular contractility. J Physiol. 2016;594:4017–4030.

39. Machhada A, Ang R, Ackland GL, Ninkina N, Buchman VL, Lythgoe MF, Trapp S, Tinkar A, Marina N, Gourine AV. Control of ventricular excitability by neurons of the dorsal motor nucleus of the vagus nerve. Heart Rhythm. 2015;12:2285–2293.

40. Machhada A, Marina N, Korsak A, Stuckey DJ, Lythgoe MF, Gourine AV. Origins of the vagal drive controlling left ventricular contractility. J Physiol. 2016;594:4017–4030.

41. Xu XL, Zhang WJ, Lu J, Kang XQ, Li M, Yu XJ. Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart. Auton Neurosci. 2006;130:6–16.

42. Machhada A, Ang R, Ackland GL, Ninkina N, Buchman VL, Lythgoe MF, Trapp S, Tinkar A, Marina N, Gourine AV. Control of ventricular excitability by neurons of the dorsal motor nucleus of the vagus nerve. Heart Rhythm. 2015;12:2285–2293.

43. Machhada A, Marina N, Korsak A, Stuckey DJ, Lythgoe MF, Gourine AV. Origins of the vagal drive controlling left ventricular contractility. J Physiol. 2016;594:4017–4030.

44. Dibner-Dunlap ME, Smith ML, Kinugawa T, Thames MD. Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure. J Am Coll Cardiol. 1996;27:358–364.

45. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation. 1998;98:1510–1516.

46. Schwarten P, Vanoli E, Stramba-Badiale M, De Ferrari GM, Billman GE, Foreman RD. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation. 1988;78:969–979.

47. Chugh SS, Reinier K, Singh T, Uy-Evano A, Socoteanu C, Peters D, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119:663–670.

48. Schwartz PJ, Vanoli E, Stramba-Badiale M, De Ferrari GM, Billman GE, Foreman RD. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation. 1988;78:969–979.

49. Panikkath R, Reinier K, Uy-Evano A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119:663–670.

50. Panikkath R, Reinier K, Uy-Evano A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119:663–670.

51. Panikkath R, Reinier K, Uy-Evano A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119:663–670.

52. Panikkath R, Reinier K, Uy-Evano A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119:663–670.

53. Panikkath R, Reinier K, Uy-Evano A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119:663–670.

54. Panikkath R, Reinier K, Uy-Evano A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119:663–670.

55. Panikkath R, Reinier K, Uy-Evano A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119:663–670.